Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy

Bone Marrow Transplantation

Volumn 21, Issue 8, 1998, Pages 829-832

  Goringe, A P ^a   Brown, S ^a   O'Callaghan, U ^a   Rees, J ^a   Jebb, S ^b   Elia, M ^b   Poynton, C H ^a,c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bone marrow transplantation; Glutamine; Veno occlusive disease; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FREE RADICAL; GLUTAMINE; GLUTATHIONE; MELPHALAN;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; DRUG INFUSION; EDEMA; FEVER; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER VEIN OBSTRUCTION; MALE; MELENA; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031945422     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701172     Document Type: Article

References (12)

1. Shulman HM, Hinterburger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after bone marrow transplantation. Blood 1995; 85: 3005-3020.
3. McDonald GB, Hinds M, Fisher L et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation; a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
4. DeLeve LD, Kuklenkamp JF. Agents causing hepatic veno-occlusive disease (HVOD) selectively kill sinusoidal endothelial cells (SECs): common mechanism through GSH depletion. Gastroenterology 1993; 104 (Suppl. 2): (Abstr. 894a).
5. Teicher BA, Crawford JM, Holden SA et al. Glutathione monoethylester can selectively protect liver from high-dose BCNU or cyclophosphamide. Cancer 1994; 74: 2879-2884.
6. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic veno-ocdusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506.
7. Nattakom TV, Charlton A, Wilmore DW. Use of vitamin E and glutamine in the successful treatment of severe veno-occlusive disease following bone marrow transplantation. Nutr Clin Pract 1995; 10: 16-18.
8. Poynton CH, Maughan TS, Jebb S, Elia M. Glycyl-L-glutamine reduces gut toxicity in bone marrow transplantation. Blood 1995; 86 (Suppl. 1): 10 (Abstr. 2258).
9. Ziegler T, Lorraine S, Young RD et al. Clinical and metabolic efficacy of glutamine supplementation parenteral nutrition after bone marrow transplantation. Ann Intern Med 1992; 116: 821-828.
10. Schloerb P, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double blind study). J Par Nutr 1993; 17: 407-413.
11. Van Zaanen HCT, van der Lelie H, Timmer JG et al. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994; 74: 2879-2884.
12. Hong RW, Rounds JD, Williams BS et al. Glutamine preserves liver glutathione after lethal hepatic injury. Surg 1992; 215: 114-119.